|
1
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H and Thiele J (eds): WHO classification of tumour
of haematopoietic and lymphoid tissues. 4th edition. Vol 2. Lyon,
pp30-36, 2017.
|
|
2
|
Höglund M, Sandin F and Simonsson B:
Epidemiology of chronic myeloid leukaemia: An update. Ann Hematol.
94 (Suppl 2):S241–247. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chereda B and Melo JV: Natural course and
biology of CML. Ann Hematol. 94 (Suppl 2):S107–S121.
2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cho SY, Kim SY, Jeon YL, Oh SH, Cho EH,
Lee WI, Cho KS and Park TS: A novel three-way Ph variant t(8;9;22)
in adult acute lymphoblastic leukemia. Ann Clin Lab Sci. 41:71–78.
2011.PubMed/NCBI
|
|
5
|
Jabbour E and Kantarjian H: Chronic
myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
Am J Hematol. 93:442–459. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Costa D, Grau J, Espinet B, Arias A, Gómez
C, López-Guerra M, Nomdedeu M and Cervantes F: Conventional and
molecular cytogenetic studies to characterize 32 complex variant
Philadelphia translocations in patients with chronic myeloid
leukemia. Oncol Lett. 17:5705–5710. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Marzocchi G, Castagnetti F, Luatti S,
Baldazzi C, Stacchini M, Gugliotta G, Amabile M, Specchia G,
Sessarego M, Giussani U, et al: Variant Philadelphia
translocations: molecular-cytogenetic characterization and
prognostic influence on frontline imatinib therapy, a GIMEMA
Working Party on CML analysis. Blood. 117:6793–6800.
2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Stagno F, Vigneri P, Del Fabro V, Stella
S, Cupri A, Massimino M, Consoli C, Tambè L, Consoli M, Agostino
Antolino and Francesco Di Raimondo: Influence of complex variant
chromosomal translocations in chronic myeloid leukemia patients
treated with tyrosine kinase inhibitors. Acta Oncol. 49:506–508.
2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Manabe M, Yoshii Y, Mukai S, Sakamoto E,
Kanashima H, Inoue T and Teshima H: A rare t(9;22;16)(q34;q11;q24)
translocation in chronic myeloid leukemia for which imatinib
mesylate was effective: A case report. Leuk Res Treatment.
2011(592519)2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
World Medical Association Declaration of
Helsinki. Ethical Principles for Medical Research Involving Human
Subjects. Bulletin of the World Health Organization. 9:373–374.
2001.
|
|
11
|
Vermeesch JR, Brady PD, Sanlaville D, Kok
K and Hastings RJ: Genome-wide arrays: quality criteria and
platforms to be used in routine diagnostics. Hum Mutat. 33:906–915.
2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
van Dongen JJ1, Macintyre EA, Gabert JA,
Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G,
Griesinger F, et al: Standardized RT-PCR analysis of fusion gene
transcripts from chromosome aberrations in acute leukemia for
detection of minimal residual disease. Report of the BIOMED-1
Concerted Action: investigation of minimal residual disease in
acute leukemia. Leukemia. 13:1901–1928. 1999.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gabert J, Beillard E, van der Velden VH,
Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela
JM, Cavé H, et al: Standardization and quality control studies of
‘real-time’ quantitative reverse transcriptase polymerase chain
reaction of fusion gene transcripts for residual disease detection
in leukemia - a Europe Against Cancer program. Leukemia.
17:2318–2357. 2003.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Beillard E, Pallisgaard N, van der Velden
VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E,
Gottardi E, Saglio G, et al: Evaluation of candidate control genes
for diagnosis and residual disease detection in leukemic patients
using ‘real-time’ quantitative reverse-transcriptase polymerase
chain reaction (RQ-PCR) - a Europe against cancer program.
Leukemia. 17:2474–2486. 2003.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Baccarani M, Deininger MW, Rosti G,
Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes
JE, Guilhot F, et al: European LeukemiaNet recommendations for the
management of chronic myeloid leukemia: 2013. Blood. 122:872–884.
2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sokal JE, Cox EB, Baccarani M, Tura S,
Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F,
et al: Prognostic discrimination in ‘good-risk’ chronic
granulocytic leukemia. Blood. 63:789–799. 1984.PubMed/NCBI
|
|
17
|
Hasford J, Baccarani M, Hoffmann V,
Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele
G, Lindoerfer D, et al: Predicting complete cytogenetic response
and subsequent progression-free survival in 2060 patients with CML
on imatinib treatment: the EUTOS score. Blood. 118:686–692.
2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hasford J, Pfirrmann M, Hehlmann R, Allan
NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL and
Ansari H: A new prognostic score for survival of patients with
chronic myeloid leukemia treated with interferon alfa. J Natl
Cancer Inst. 90:850–858. 1998.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cross NC, White HE, Colomer D, Ehrencrona
H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K,
Dulucq S, et al: Laboratory recommendations for scoring deep
molecular responses following treatment for chronic myeloid
leukemia. Leukemia. 9:999–1003. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chen Z, Morgan R, Berger CS, Pearce-Birge
L, Stone JF and Sandberg AA: Identification of masked and variant
Ph (complex type) translocations in CML and classic Ph in AML and
ALL by fluorescence in situ hybridization with the use of bcr/abl
cosmid probes. Cancer Genet Cytogenet. 70:103–107. 1993.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Bennour A, Sennana H, Laatiri MA, Elloumi
M, Khelif A and Saad A: Molecular cytogenetic characterization of
variant Philadelphia translocations in chronic myeloid leukemia:
genesis and deletion of derivative chromosome 9. Cancer Genet
Cytogenet. 194:30–37. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gorusu M, Benn P, Li Z and Fang M: On the
genesis and prognosis of variant translocations in chronic myeloid
leukemia. Cancer Genet Cytogenet. 173:97–106. 2007.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Koshiyama DB, Capra ME, Paskulin GA, Rosa
RF, Oliveira CA, Vanelli T, Fogliatto LM and Zen PR: Cytogenetic
response to imatinib treatment in Southern Brazilian patients with
chronic myelogenous leukemia and variant Philadelphia chromosome.
Ann Hematol. 92:185–189. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hossfeld DK and Köhler S: New
translocations in chronic granulocytic leukaemia: t(X;22)(p22;q11)
and t(15;22)(q26;q11). Br J Haematol. 41:185–191. 1979.PubMed/NCBI View Article : Google Scholar
|
|
25
|
El-Zimaity MMT, Kantarjian H, Talpaz M,
O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D,
Ferrajoli A, Hayes K, et al: Results of imatinib mesylate therapy
in chronic myelogenous leukaemia with variant Philadelphia
chromosome. Br J Haematol. 125:187–195. 2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mitelman F and Levan G: Clustering of
aberrations to specific chromosomes in human neoplasms. Hereditas.
89:207–232. 1978.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Levan G and Mitelman F: The different
origin of primary and secondary chromosome aberrations in cancer.
Haematol Blood Transfus. 26:160–166. 1981.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Fitzgerald PH, McEwan C, Fraser J and
Beard ME: A complex Ph1 translocation in a patient with primary
thrombocythaemia. Br J Haematol. 47:571–575. 1981.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Morris CM, Rosman I, Archer SA, Cochrane
JM and Fitzgerald PH: A cytogenetic and molecular analysis of five
variant Philadelphia translocations in chronic myeloid leukemia.
Cancer Genet Cytogenet. 35:179–197. 1988.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kanakasetty GB, Kuntejowdahalli L, Thanky
AH, Dasappa L, Jacob LA, Mallekavu SB and Kumari P: Predictive and
Prognostic implications of variant Philadelphia translocations in
CML: Experience from a tertiary oncology center in Southern India.
Clin Lymphoma Myeloma Leuk. 17:52–59. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Albano F, Anelli L, Zagaria A, Coccaro N,
Casieri P, Rossi AR, Vicari L, Liso V, Rocchi M and Specchia G: Non
random distribution of genomic features in breakpoint regions
involved in chronic myeloid leukemia cases with variant t(9;22) or
additional chromosomal rearrangements. Mol Cancer.
9(120)2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Becher R, Qiu JY, Parr A, Wendehorst E and
Schmidt CG: Seven variants including four new Philadelphia
translocations. Cancer Genet Cytogenet. 44:181–186. 1990.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Bonifacio M, Elena Ch, D'Adda M, Scaffidi
L, Pucci M, Aprili F, Ferrari J, Tucci A, Stagno F, Scortechini AR,
et al: Do not miss karyotyping at chronic myeloid leukemia
diagnosis: An Italian Campus CML study on the role of complex
variant translocations. Blood. 136 (Suppl 1):43–44. 2020.
|
|
34
|
Brahmbhatt MM, Trivedi PJ, Dalal EN, Patel
DM, Purani SS, Shukla SN, Shah PM and Patel PS: ABL/BCR gene
variant with two-step mechanism: Unusual localization and
rare/novel chromosomal rearrangements in CML patients. J Assoc
Genet Technol. 37:69–75. 2011.PubMed/NCBI
|
|
35
|
Sessarego M, Fugazza G, Bruzzone R and
Patrone F: Variant Philadelphia Chromosome Translocations are
Frequently Associated with Additional Structural Abnormalities.
Cancer Genet Cytogenet. 73:57–59. 1994.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Trivedi P, Varma P, Patel D, Ladani D,
Patel D, Kazi M, Patel N and Patel P: Clinical Implications of
simultaneous occurrence of variant Philadelphia translocations in
chronic myeloid leukemia. J Assoc Genet Technol. 45:61–65.
2019.PubMed/NCBI
|
|
37
|
Hochhaus A, Baccarani M, Silver RT,
Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE,
Deininger MW, Guilhot F, et al: European LeukemiaNet 2020
recommendations for treating chronic myeloid leukemia. Leukemia.
34:966–984. 2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Jabbour E, Kantarjian HM, O'Brien S, Shan
J, Quintás-Cardama A, Garcia-Manero G, Rios MB and Cortes JE:
Front-line therapy with second-generation tyrosine kinase
inhibitors in patients with early chronic phase chronic myeloid
leukemia: what is the optimal response? J Clin Oncol. 29:4260–4265.
2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Eiring AM, Khorashad JS, Morley K and
Deininger MW: Advances in the treatment of chronic myeloid
leukemia. BMC Med. 9(99)2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Hehlmann R: The New ELN recommendations
for treating CML. J Clin Med. 9(3671)2020.PubMed/NCBI View Article : Google Scholar
|
